Drug Monograph

Drug/Drug Class:	**Morphine Sulfate injection, solution / Narcotic Analgesic**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Morphine Sulfate is supplied as 2 mg/mL, 4 mg/mL, 8mg/mL, 10 mg/mL, and 15 mg/mL injection solution.
Manufacturer:	Hospira, Inc., Lake Forest, IL 60045
Indications:	Morphine sulfate is indicated to manage pain that is not alleviated by non-narcotic analgesics.
Costs:	$ 1.54 per mL of Morphine sulfate oral solution. Wholesale Acquisition Cost
Summary of Findings:	The Division recommends Open Access status for these products.
Status Recommendation:	☐ Prior Authorization (PA) Required ☒ Open Access ☐ Clinical Edit ☐ PDL
Type of PA Criteria:	☐ Increased Risk of ADE ☒ No PA Required ☐ Appropriate Indications ☐ Under Solicitation

Prepared By: Mary Jo Curtis, Pharm. D. candidate.
Date: November 12, 2012

© 2013 Xerox Heritage, LLC All Rights Reserved.